Rewriting futures
Developing new medicines
for people living with
inflammatory diseases
Driven to transform the lives of people with inflammatory diseases
By tackling the toughest protein targets with selective inhibitors, we’re creating the next generation of oral precision medicines – innovative therapies designed to redefine treatment, offering people safer, more effective options to manage their conditions.
Unlocking the previously undruggable SH2 domain
SH2 domains are essential for regulating the localization and activity of proteins and play a central role in mediating cellular signals that trigger specific responses. Dysregulation of the cellular pathways that utilize SH2-domain containing proteins drives certain disorders, including inflammatory diseases. Once considered undruggable, our platform integrates new chemical approaches and technologies to enable the successful development of therapies to inhibit SH2 domains, resulting in the inhibition of dysregulated cellular pathways.
Latest news
- Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting
- Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
- Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors